Table 1 Characteristics of studies included in the final meta-analysis of Ki-67 expression and prognosis of lymphoma
First author | Year | Country | Patient (P/N) | Age (year) | Disease subtype | High Ki-67 expression threshold | Antibody | Sample source | Therapy regimen | HR (95% CI) of OS | HR (95% CI) of DFS | Quality score | Study type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Salek | 2013 [40] | Czech | 210 (74/136) | NA | MCL | 30% (estimated) | Anti-MIB-1 | WTS | From no chemotherapy to intensive induction with or without ASCT | 2.05 (1.45-2.89) | NA | 7 | R |
| Â | Â | Â | Â | Â | Â | Â | Â | Â | R-treated | 2.63 (1.72-4.04) | NA | Â | Â |
Li | 2013 [5] | America | 43 (18/25) | 46 median | NK/TL | 60% (image analysis) | Anti-Ki-67 | WTS | CHOP + RT mostly | 5.15 (1.52-17.58) | 3.43 (1.1-10.72) | 6 | R |
Geisler | 2012 [6] | Europe | 122 (33/89) | 56 median | MCL | 33% (estimated) | NA | NA | R-CHOP/R-AraC + ASCT | 2.64 (1.46-4.77) | 2.32 (1.39-3.89) | 7 | p |
Li | 2012 [7] | China | 118 (55/63) | 53 median | DLBCL | 70% (estimated) | Anti-Ki-67 | WTS | R-CHOP + RT | 1.284 (1.075-1.535) | 3.38 (1.64-6.93) | 8 | R |
Salles | 2011 [19] | Europea and America | 1138 (627/511) | NA | DLBCL | 75% (estimated) | NA | TMAs | R-CHOP | 1.8 (1.1-2.9) | NA | 8 | p |
| Â | Â | Â | Â | Â | Â | Â | Â | Â | CHOP | 1 (0.6-1.5) | NA | Â | Â |
Gaudio | 2011 [20] | Italy | 111 (38/73) | 60 median | DLBCL | 80% (estimated) | NA | WTS | R-CHOP | 2.1 (1.6-4.8) | 2.6 (1.2-3.8) | 6 | R |
| Â | Â | Â | Â | Â | Â | Â | Â | Â | CHOP | 2.1 (0.9-4.3) | NA | Â | Â |
Song | 2011 [21] | Korea | 65 (31/34) | 59 median | DLBCL | 70% (estimated) | Anti-Ki-67 | WTS | HD-MTx + WBRT | 1.657 (0.893-3.259) | NA | 5 | R |
Ott | 2010 [22] | Europe | 386 (283/103) | 68 median | DLBCL | 75% (estimated) | Anti-MIB-1 | TMAs | R-CHOP | 0.8 (0.4-1.5) | 0.8 (0.5-1.4) | 7 | P |
| Â | Â | Â | Â | Â | Â | Â | Â | Â | CHOP | 1.1 (0.6-1.9) | 0.9 (0.5-1.4) | Â | Â |
Barros | 2010 [23] | Germany | 87 (53/34) | 14 median | HL | 50% (image analysis) | Anti-MIB-1 | TMAs | ABVD + RT | NA | NA | 7 | R |
Goy | 2010 [8] | Europea and America | 67 (16/51) | 66 median | MCL | 50% (estimated) | Anti-Ki-67 | WTS | Bortezomib | 1.93 (0.9-4.1) | NA | 5 | P |
Yoon | 2010 [24] | Korea | 144 (46/98) | 54 median | DLBCL | 85% (estimated) | Anti-Ki-67 | WTS | R-CHOP + partial RT | 2.876 (0.972-8.508) | 2.9 (1.26-6.7) | 9 | P |
Chung | 2010 [25] | Canada | 80 (22/58) | 64 median | MCL | 50% (estimated) | Anti-Ki-67 | WTS | CHOP mostly | 4.4 (2.24-8.64) | NA | 4 | R |
Garcia | 2008 | America | 76 (38/38) | 62 median | MCL | 20% (estimated) | Anti-Ki-67 | WTS | R-hyper-CVAD | NA | NA | 9 | P |
His | 2008 | America | 52 (17/35) | 56 median | MCL | 35% (estimated and image analysis) | Anti-Ki-67 | WTS | R-CHOP + ASCT | NA | 2.46 (1.14-5.31) | 9 | P |
Hasselblom | 2008 [10] | Sweden | 199 (149/50) | 66 median | DLBCL | 49% (image analysis) | Anti-Ki-67 | WTS | CHOP/CHOP like + partial RT | 0.625 (0.256-1.11) | NA | 8 | P |
Szczuraszek | 2008 [28] | Poland | 53 (24/29) | 56.3 mean | NHL | 30% (image analysis) | Anti-MIB-1 | WTS | NR | 2.567 (1.144-5.761) | NA | 6 | R |
Determann | 2008 [29] | Europe | 249 (nr) | NA | MCL | 10% (estimated) | Anti-MIB-1 or Ki-S5 | NA | CHOP or MCP or R-CHOP | 1.27 (1.15-1.39) | NA | 6 | P |
Kim | 2007 [30] | Korea | 50 (27/23) | 41 median | NK/TL | 65% (estimated) | Anti-MIB-1 | WTS | CHOP + partial RT | 4.33 (1.108-16.918) | 3.23 (1.07-9.72) | 8 | R |
Bahnassy | 2006 [31] | Egypt | 50 (35/15) | 45 median | NHL | 30% (estimated) | Anti-MIB-1 | WTS | CHOP + partial RT | 0.696 (0.274-1.766) | NA | 7 | R |
Jerkeman | 2004 [9] | Europe | 185 (69/116) | NA | DLBCL | 60% (estimated) | Anti-MIB-1 | WTS | CHOP or M-BACOP | 0.56 (0.3-1) | 0.53 (0.31-0.91) | 5 | P |
Martinez | 2004 [32] | Spain | 80 (nr) | NA | MCL | 50% (estimated) | Anti-MIB-1 | WTS | NA | 4.4 (1.9-9.9) | NA | 4 | R |
Seki | 2003 [33] | Japan | 27 (14/13) | 59.7 mean | DLBCL | 40% (estimated) | Anti-Ki-67 | WTS | CHOP | Â | NA | 6 | R |
Provencio | 2003 [34] | Spain | 42 (nr) | 29mean | HL | 20% (NA) | NA | WTS | MOPP or ABVD | 3.3 (0.85-12.5) | 2.21 (0.92-5.33) | 4 | R |
Raty | 2002 [35] | Finland | 96 (31/65) | NA | MCL | 26% (estimated) | Anti-Ki-67 | WTS | CHOP or M-BACOD mostly + partial RT and SCT | 3.25 (1.9-5.58) | NA | 5 | R |
Sanchez | 1998 [36] | Spain | 77 (36/41) | 62 median | DLBCL | 20% (image analysis) | Anti-MIB-1 | WTS | CHOP + partial RT or surgery | 1.74 (1.064-2.848) | 1.06 (0.48-2.33) | 6 | R |
Morente | 1997 [37] | Spain | 140 (nr) | NA | HL | Continuous variable (image analysis) | Anti-MIB-1 | WTS | MOPP or ABVD + RT | 1.04 (1–1.08) | NA | 4 | R |
Miller | 1994 [38] | America | 60 (11/49) | NA | DLBCL | 80% (estimated) | Anti-Ki-67 | WTS | CHOP, M-BACOD, ProMACE-CytaBOM, or M-BACOP | 5.9 (2.2-16.1) | NA | 8 | P |
Slymen | 1990 [39] | America | 105 (19/86) | 58 median | DLBCL | 60% (estimated) | Anti-Ki-67 | WTS | CHOP, M-BACOD, ProMACE-CytaBOM, CVP or M-BACOP + partial RT or surgery | 3.64 (1.66-7.95) | NA | 8 | R |